Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A

Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A

SSSE:605199
5.20
CNY
-0.15
(-2.80%)
-1.01EPS
2.08BMarket Cap
Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A
SSE:605199
(Shanghai Stock Exchange)

Recent

price

5.20

P/E

ratio

- -

div

yld

1.36%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
8.12
3.85
3.03
3.58
3.06
3.38
3.71
4.96
3.55
2.26
1.56
Revenue per Share
0.56
0.13
0.31
0.33
0.32
0.18
0.21
0.03
-0.69
-0.72
-1.02
Basic EPS, GAAP
0.4
-0.4
-0.13
0.24
-0.15
-0.09
-0.38
-1.27
-0.77
0.13
- -
Free Cash Flow per Basic Share
0.26
0.08
0.25
0.23
0.02
0.18
0.04
0.09
0.23
0.08
0.07
Dividend per Share
2.14
3.14
1.68
1.79
2.29
2.32
2.53
2.56
1.75
1.03
0.75
Book Value per Share
0.31
2.22
1.42
1.56
1.97
1.98
2.14
1.92
1.04
0.35
0.07
Tangible Book Value per Share
60
170
324
365
380
401
408
362
398
399
404
Basic Weighted Avg Shares
487
655
984
1,306
1,162
1,354
1,515
1,795
1,414
901
630
Sales/Revenue/Turnover
10.66
7.48
12.82
12.13
13.25
6.32
8
4.21
-16.61
-17.74
-41.85
Operating Margin (%)
28
29
36
42
44
48
51
59
78
100
- -
Depreciation Expense
34
22
101
120
122
72
86
11
-274
-287
-411
Net Income, GAAP
21.59
37.46
15.14
15.4
9.59
14.83
12.84
37.19
- -
- -
- -
Effective Tax Rate (%)
6.93
3.38
10.22
9.21
10.46
5.33
5.66
0.6
-19.42
-31.9
-65.33
Profit Margin (%)
-81
-28
175
147
414
293
190
285
-219
-560
-714
Working Capital
105
70
31
17
53
4
178
739
592
547
506
LT Debt
129
351
605
644
916
931
1,015
1,063
743
458
346
Total Equity
- -
4.84
15.5
15.13
11.99
4.3
5.37
0.91
- -
- -
- -
Return on Invested Capital (%)
- -
7.3
17.37
17.06
13
6.58
6.54
0.8
- -
- -
- -
Return on Capital (%)
- -
9.22
21.03
19.28
15.58
7.82
8.82
1.06
-31.83
-51.65
-80.37
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
626
532
543
LT Borrowings
545
615
505
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
400
400
400
Market Capitalization
3,049
2,733
2,077

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
881
853
740
Cash, Cash Equivalents & STI
78
77
39
Accounts Receivable, Net
418
423
365
Inventories
254
227
206
Total Current Liabilities
1,441
1,364
1,455
Payables & Accruals
- -
- -
- -
ST Debt
626
532
543
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-10.61%
-38.31%
Free Cash Flow
- -
69.73%
-117.42%
Net Income, GAAP
- -
-546.74%
4.71%
Sales/Revenue/Turnover
- -
-2.12%
-36.27%
Total Cash Common Dividend
- -
198.02%
-63.59%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
471
418
144
381
1,414
2025
337
171
- -
218
901
2026
146
95
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.03
-0.4
-0.39
-0.69
2025
0.06
-0.05
- -
-0.69
-0.72
2026
-0.07
-0.21
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.16
0.02
0.23
2025
0.02
0.02
- -
0.01
0.08
2026
0.02
0.02
- -
- -
- -
Business
Hainan Huluwa Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceuticals primarily focused on children's medicines for respiratory and digestive systems, anti-infectives, nutritional supplements, health foods, special medical foods, and medical devices. Its core products include Xiaoer Feire Kechuan Granules, Changyanning Granules and Capsules, Keke Tablets, pediatric lung heat cough asthma granules, bromhexine hydrochloride for injection, compound Banlangen granules, omeprazole enteric-coated capsules, omeprazole sodium for injection, cefixime dispersible tablets, compound dendrobium granules, compound fresh dendrobium granules, compound cold cough tablets, compound lysine granules, compound anti-lung cream, valsartan amlodipine tablets, oseltamivir phosphate capsules, and ibuprofen suspension; the company also offers gynecological, cardiovascular, and neurological medicines under the Huluwa brand. Founded in 2005 and headquartered in Haikou, Hainan Province, China, at No. 30 Andu 1st Road, Xiuying District, the company primarily serves the domestic Chinese market with approximately 2,100 employees. Recent developments include entering an agreement to acquire a 51% stake in Jiangxi Rongxing Pharmaceutical Co., Ltd., obtaining registration certificates for Cefprozil for Oral Suspension and amendments for Cefotaxime Sodium for Injection, and pursuing R&D investments in new drug formulations alongside planned expansions into Southeast Asia through distributor partnerships.